SK Biopharmaceuticals Co (326030.KS) Osake Kurssi
SK Biopharmaceuticals Co Kurssi
Liikevaihto on kasvanut 25,7 % vuodessa viimeisten 9 vuoden aikana 706,74 Mrd. KRW:een. Osakekohtainen tulos on kasvanut 42,4 % vuodessa viimeisten 4 vuoden aikana. SK Biopharmaceuticals Con nettomarginaali on nyt 37,8 %, noussut 15,5 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 158 100,00 KRW, eli yli nykyhintaa 113,4 %. 22 analyytikosta 18 suosittaa ostoa — kokonaiskonsensus on Osta.
SK Biopharmaceuticals Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
SK Biopharmaceuticals Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset SK Biopharmaceuticals Co -osakkeesta
The business model of SK Biopharmaceuticals Co Ltd revolves around the development and commercialization of innovative pharmaceutical products. As a global biopharmaceutical company, SK Biopharmaceuticals focuses on researching, discovering, and developing novel treatments for various diseases. This includes conducting rigorous clinical trials, obtaining regulatory approvals, and engaging in strategic partnerships for the commercialization of their products. With a strong emphasis on research and development, SK Biopharmaceuticals aims to bring forth cutting-edge therapies to improve patients' lives and address unmet medical needs.
SK Biopharmaceuticals Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of SK Biopharmaceuticals Co Ltd in the market include major players like Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies, along with SK Biopharmaceuticals, are engaged in the research, development, and commercialization of innovative biopharmaceutical products. With its strong portfolio and market presence, SK Biopharmaceuticals competes fiercely and continuously strives to maintain its position among these industry giants.
SK Biopharmaceuticals Co Ltd is a leading biopharmaceutical company with a rich history and background. Established in 1993, the company specializes in research, development, and manufacturing of innovative therapeutics. Headquartered in South Korea, SK Biopharmaceuticals has expanded its global presence through strategic partnerships and collaborations. With a focus on neurological disorders and other therapeutic areas, the company has developed breakthrough drugs such as XYREM®, which is used to treat narcolepsy. SK Biopharmaceuticals Co Ltd has built a strong reputation for its cutting-edge research, commitment to scientific excellence, and dedication to improving patients' lives.
SK Biopharmaceuticals Co Ltd has achieved several significant milestones. Firstly, the company successfully developed and obtained approval for its innovative epilepsy treatment, cenobamate, in the United States. This achievement marks a major breakthrough in the treatment of epilepsy. Additionally, SK Biopharmaceuticals Co Ltd has entered into numerous global partnerships and collaborations, expanding its reach in the pharmaceutical industry. The company has also made substantial progress in its pipeline, advancing the development of various neurologic and psychiatric disorders treatments. With these achievements, SK Biopharmaceuticals Co Ltd has further solidified its position as a leading player in the biopharmaceutical sector.
SK Biopharmaceuticals Co Ltd is primarily present in South Korea.
SK Biopharmaceuticals Co Ltd represents values such as innovation, integrity, and collaboration. The company's corporate philosophy revolves around creating innovative solutions to improve the lives of patients worldwide. SK Biopharmaceuticals Co Ltd is committed to conducting business with the utmost integrity, ensuring transparency, and adhering to ethical standards. The company strives to foster a collaborative environment, working together with partners and stakeholders to drive advancements in the biopharmaceutical industry. With a focus on research and development, SK Biopharmaceuticals Co Ltd aims to bring groundbreaking treatments and therapies to patients, reflecting its dedication to improving global healthcare.
Analyytikot asettavat tällä hetkellä SK Biopharmaceuticals Co-osakkeelle keskimääräisen tavoitehinnan 147 198,75 KRW (mediaani: 158 100,00 KRW), mikä merkitsee +98,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 22 analyytikkoarvioon.
SK Biopharmaceuticals Co Analyytikkojen kursstavoitteet 2026
22 analyytikkoa arvioi tällä hetkellä SK Biopharmaceuticals Co-osaketta: 18 suosittaa ostoa, 3 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat SK Biopharmaceuticals Co-yhtiöltä 974,86 Mrd. KRW liikevaihtoa ja 4 154,34 KRW osakekohtaista tulosta.
SK Biopharmaceuticals Co Analyytikkojen kursstavoitteet 2026
Nykyisellä valuuttakurssilla SK Biopharmaceuticals Co-osake noteerataan hintaan 49,16 EUR (74 100,00 KRW).
SK Biopharmaceuticals Co-osake (326030.KS) on listattuna 1 pörssissä, muun muassa: KOSPI (Seoul) (326030.KS).
SK Biopharmaceuticals Co Ltd (SK biopharm) is a leading South Korean company specializing in the development and commercialization of innovative drugs for the treatment of central nervous system (CNS) disorders and other major diseases. The company is committed to promoting better health for patients worldwide through its research and development. SK biopharm has several business areas, including research and development (R&D), production, and distribution of pharmaceuticals. The R&D division is the core of the company, focusing on the discovery, development, and commercialization of new drugs and therapeutic approaches. SK biopharm invests significantly in R&D and has built a comprehensive research platform that combines expertise in medicine, chemistry, pharmacology, toxicology, and biology. SK biopharm offers a wide range of products available in various countries worldwide. One of the company's key products is the anticonvulsant XCOPRI® (Cenobamate), which is approved in the US, Europe, and China. XCOPRI® was developed to help patients with partial-onset seizures, one of the most common forms of epilepsy. XCOPRI® has proven to be highly effective and safe, showing promising results in clinical trials. Another important product from SK biopharm is the antidepressant Vilazodone (trade name Viibryd), approved for the treatment of depression in adults. Viibryd has shown good efficacy due to its unique dual action on serotonin receptors and serotonin transporters. SK biopharm also has a wide range of products in its R&D pipeline, including new therapies for the treatment of epilepsy, schizophrenia, and pain. SK biopharm pursues a global expansion strategy and has offices in North America, Europe, and Asia. The company has established strategic partnerships with some of the world's leading pharmaceutical companies to accelerate the development and commercialization of its products worldwide. SK biopharm has also formed partnerships with academic institutions and research institutes around the world to drive innovation in medicine. To foster growth, SK biopharm has established a strong corporate culture that promotes innovation, collaboration, and entrepreneurial virtues. The company has an experienced management team and a dedicated research team focused on developing drugs that have the potential to improve the lives of people worldwide. Overall, SK biopharm has an impressive track record in developing and commercializing innovative drugs for a variety of CNS disorders. With its R&D pipeline, wide product range, and strategic partnerships, SK biopharm is well-positioned to continue helping patients worldwide and promoting better health for all.
odotettu liikevaihto SK Biopharmaceuticals Co on 974,86 Mrd. KRW. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto SK Biopharmaceuticals Co on 325,34 Mrd. KRW. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
SK Biopharmaceuticals Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 17,84. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SK Biopharmaceuticals Co-osakkeen arvostusta.
SK Biopharmaceuticals Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,95. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii SK Biopharmaceuticals Co-osakkeen arvostuskennuslukuna.
SK Biopharmaceuticals Co:n Eulpool-laatuscore on 4/10.
SK Biopharmaceuticals Co:n ISIN on KR7326030004. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
SK Biopharmaceuticals Co:n ticker on 326030.KS. Tämä pörssinoteeraus käytetään SK Biopharmaceuticals Co-osakkeiden kauppaan pörssissä.
SK Biopharmaceuticals Co osake
SK Biopharmaceuticals Co vertaisryhmä
SK Biopharmaceuticals Co Ticker
SK Biopharmaceuticals Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi SK Biopharmaceuticals Co:sta
Meidän osakeanalyysimme SK Biopharmaceuticals Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut SK Biopharmaceuticals Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: